Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,821.00
Bid: 6,821.00
Ask: 6,822.00
Change: 27.00 (0.40%)
Spread: 1.00 (0.01%)
Open: 6,779.00
High: 6,873.00
Low: 6,761.00
Yest. Close: 6,794.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

FTSE 100 movers: Astrazeneca soars on new diabetes research, RBS higher on upgrade

AstraZeneca topped the risers as it committed $40m to backing phase 2a trials for a new diabetes drug - a form of long-acting insulin that only needs to be administered once week. Glaxosmithkline was boosted by news it plans to sell approximately half of its 12.4% stake in Aspen Pharmacare Holdings.

12 Mar 15 14:00

MARKET COMMENT: FTSE 100 Slides On US Jobs Data, Miners Weigh

6 Mar 15 16:51

UK MIDDAY BRIEFING: Thomas Cook Soars On Chinese Investment

6 Mar 15 12:20

UK WINNERS & LOSERS: Thomas Cook Up As China's Fosun Takes Stake

6 Mar 15 11:37

TOP NEWS: China's Fosun Seals Thomas Cook Partnership With 10% Stake

6 Mar 15 11:20

MARKET COMMENT: Miners Weigh On FTSE 100 Ahead Of US Nonfarm Payrolls

6 Mar 15 10:46

UK MORNING BRIEFING: Chinese Interest Lifts Thomas Cook And Afren

6 Mar 15 08:29

AstraZeneca keeps 2015 outlook after financial reporting change

LONDON, March 6 (Reuters) - Drugmaker AstraZeneca said on Friday it would change the way it reported results with effect from the first quarter of 2015 to make revenue from so-called externalisation deals more visible to investors. The move means the company will now focus on total revenue

6 Mar 15 07:58

MARKET COMMENT: London Set For Soft Opening With US Jobs In Focus

6 Mar 15 07:34

AstraZeneca Confirms Revenue Guidance As It Tweaks Financial Reporting

6 Mar 15 07:18

Bristol's $1 bln Bavarian deal may signal cancer vaccine revival

By Ben Hirschler LONDON, March 4 (Reuters) - The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic . The agreement gives the U.S. drugmaker an exclusive option to the Danish biotech firm's ther

4 Mar 15 15:37

Stryker's $2 bln buyback plan deflates Smith & Nephew bid hopes

LONDON, March 3 (Reuters) - Plans by Stryker to launch a new $2 billion share buyback programme punctured hopes the U.S. surgical implant firm would bid for rival Smith & Nephew, sending shares in the British group some 5 percent lower on Tuesday. "It probably tells you that the prospect of

3 Mar 15 15:09

London pre-open: Positive start expected after record close on Wall Street

UK stocks are expected to open with modest gains on Tuesday following a decent performance on Wall Street the night before, as investors watch corporate earnings on a quiet day for economic data. City sources predict the FTSE 100 will open 10 points higher than Monday's close of 6,940.64. Both the

3 Mar 15 07:50

AstraZeneca completes acquisition of rights to Activis

AstraZeneca has completed its acquisition of the rights to Activis' branded respiratory business in the US and Canada. The company paid Activis initial consideration worth $600m as well as an extra $100m for a number of contractual consents and approvals. According to an investor note released on T

3 Mar 15 07:10

U.S. judge denies Ranbaxy bid to reinstate approvals for Valcyte, Nexium copies

MUMBAI, Feb 28 (Reuters) - A U.S. federal judge has denied Indian generic drugmaker Ranbaxy Laboratories Ltd's bid to reinstate approvals granted to it to launch the first copies of the heartburn drug Nexium and the antiviral Valcyte, a court document showed. Judge Beryl Howell of the Unit

28 Feb 15 05:38

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.